Skip to main content
SpringerLink
Log in

Beim HPV-assoziierten Oropharynxkarzinom ist die Radiochemotherapie mit Cisplatin der Bioradiotherapie mit Cetuximab in Bezug auf das Gesamtüberleben überlegen

In HPV-associated oropharyngeal cancer, chemoradiotherapy with cisplatin is superior to bioradiotherapy with cetuximab in terms of overall survival

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mirghani H, Blanchard P (2018) Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clin Transl Radiat Oncol 8:4–11

    Article  PubMed  Google Scholar 

  3. Lefebvre JL, Pointreau Y, Rolland F et al (2013) Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 31:853–859

    Article  CAS  PubMed  Google Scholar 

  4. Hitt R, Mesia R, Grau JJ et al (2016) Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer(LAUHNC). J Clinoncol 34(supp):abst 6001

    Article  Google Scholar 

  5. Geoffrois L, De Raucourt ML et al (2018) Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol 36:3077–3083

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Strahlenklinik, Universitätsstraße 27, 91054, Erlangen, Deutschland

    Sabine Semrau

Authors
  1. Sabine Semrau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabine Semrau.

Ethics declarations

Interessenkonflikt

S. Semrau gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikationen

Mehanna H, Robinson M, Hartley A et al (2018) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALate HPV): an open-label randomized controlled phase 3 trial. Lancet. 2019;393:51–60, Published Online November 15, 2018

Gillison ML, Trotti AM, Harris J et al (2018) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal Cancer (NRG Oncology RTOG 1016): a randomized, multicentre, non-inferiority trial, Lancet. 2019;393:40–50, Published Online November 15, 2018

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Semrau, S. Beim HPV-assoziierten Oropharynxkarzinom ist die Radiochemotherapie mit Cisplatin der Bioradiotherapie mit Cetuximab in Bezug auf das Gesamtüberleben überlegen. Strahlenther Onkol 195, 447–449 (2019). https://doi.org/10.1007/s00066-019-01441-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01441-w

Search

Navigation